- Genetic mutations such as BTKC481S mutation and PLCG2 mutation- Tumor microenvironment changes - High levels of BCL2 expression- Upregulation of signaling pathways including PI3K/Akt/mTOR, MALT1, IRAK4, and SYK. This evidence concerns the gene MTOR and neoplasm.